Your browser doesn't support javascript.
loading
Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.
Kruse, Morgan; Wildner, Rebecca; Barnes, Gisoo; Martin, Monique; Mueller, Udo; Lo-Coco, Francesco; Pathak, Ashutosh.
Affiliation
  • Kruse M; Optum, Cambridge, Massachusetts, United States of America.
  • Wildner R; Optum, Cambridge, Massachusetts, United States of America.
  • Barnes G; Teva Pharmaceuticals, Frazer, Pennsylvania, United States of America.
  • Martin M; MapiGroup, Uxbridge, United Kingdom.
  • Mueller U; Teva Pharmaceuticals, Ulm, Germany.
  • Lo-Coco F; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
  • Pathak A; Teva Pharmaceuticals, Frazer, Pennsylvania, United States of America.
PLoS One ; 10(8): e0134587, 2015.
Article in En | MEDLINE | ID: mdl-26267454
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Promyelocytic, Acute / Antineoplastic Combined Chemotherapy Protocols Type of study: Health_economic_evaluation / Prognostic_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2015 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Promyelocytic, Acute / Antineoplastic Combined Chemotherapy Protocols Type of study: Health_economic_evaluation / Prognostic_studies Limits: Female / Humans / Male Country/Region as subject: Europa Language: En Journal: PLoS One Journal subject: CIENCIA / MEDICINA Year: 2015 Document type: Article Affiliation country: United States Country of publication: United States